Journal of Adolescent Health
Volume 45, Issue 1 , Pages 70-76 , July 2009

Hyperprolactinemia-Related Adverse Events Associated with Antipsychotic Treatment in Children and Adolescents

  • Jeanette M. Jerrell, Ph.D.

      Affiliations

    • Department of Neuropsychiatry, University of South Carolina School of Medicine, Columbia, South Carolina
    • Corresponding Author InformationAddress correspondence to: Jeanette M. Jerrell, Ph.D., Department of Neuropsychiatry and Behavioral Science, University of South Carolina School of Medicine, 3555 Harden Street Ext., CEB 301, Columbia, SC 29203.
    • ,
  • Janice Bacon, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, University of South Carolina School of Medicine, Columbia, South Carolina
    • ,
  • Judith T. Burgis, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, University of South Carolina School of Medicine, Columbia, South Carolina
    • ,
  • Seema Menon, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, University of South Carolina School of Medicine, Columbia, South Carolina

Received 25 February 2008 ,Accepted 24 November 2008.

References 

  1. Mancini T, Casaneuva FF, Giustina A. Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin N Am. 2008;37:67–99
  2. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinemia: mechanisms, clinical features, and management. Drugs. 2004;64(20):2291–2314
  3. Molitch ME. Disorders of PRL secretion. Endocrinol Metab Clin N Am. 2001;30(3):585–610
  4. Molitch ME. Medication-induced hyperprolactinemia. Mayo Clinic Proc. 2005;80(8):1050–1057
  5. Romeo JH, Dombrowski R, Kwak YS, et al. Hyperprolactinemia and verapamil: prevalence and potential association with hypogonadism in men. Clin Endocrinol (Oxf). 1996;45(5):571–575
  6. Byerly M, Suppes T, Tran QV, Baker RA. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders. J Clin Psychopharmacol. 2007;27(6):639–661
  7. McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf. 2006;5(1):157–168
  8. Baker S, Barlow S, Cochran W, et al. Overweight children and adolescents: a clinical report of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2005;40:533–543
  9. Findling RL, Steiner H, Weller EB. Use of antipsychotics in children and adolescents. J Clin Psychiatry. 2005;66(Suppl 7):29–40
  10. Patel NC, Crismon ML, Hoagwood K, et al. Unanswered questions regarding atypical antipsychotic use in aggressive children and adolescents. J Child Adolesc Psychopharm. 2005;15:270–284
  11. Zito JM, Safer DJ, dosReis S, et al. Psychotropic practice patterns for youth: A 10-year perspective. Arch Pediatr Adolesc Med. 2003;157:17–25
  12. Toren P, Ratner S, Laor N, et al. Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. Drug Safety. 2004;27(14):1135–1156
  13. Goodnick PJ, Rodriguez L, Santana O. Antipsychotics: impact on prolactin levels. Expert Opin Pharmacother. 2002;3(10):1381–1391
  14. Kim KS, Pae CU, Chae JH, et al. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatr. 2002;63(5):408–413
  15. Tohen M, Kryzhanovskaya L, Carlson G, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry. 2007;164(10):1547–1556
  16. Kelly DL, Love RC, Mackowick M, et al. Atypical antipsychotic use in a state hospital inpatient adolescent population. J Child Adolesc Psychopharmacol. 2004;14:75–85
  17. Cheng-Shannon J, McGough JJ, Pataki C, et al. Second generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol. 2004;14:372–394
  18. Correll CU, Penzner JB, Parikh UH, et al. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatric Clin N Am. 2006;15:177–206
  19. McIntyre RS, Konarski JZ. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry. 2005;66(Suppl 3):28–36
  20. Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2006;45:771–791
  21. Hu XH, Bull SA, Hunkeler EM, et al. Incidence and duration of side effects and those rated as bothersome with SSRI treatment for depression: patient report versus physician estimate. J Clin Psychiatry. 2004;65:959–965
  22. Burke MJ, Lincoln J. Mood disorders. In:  Bakel RE,  Bope ET editor. Conn's Current Therapy 2006. Philadelphia, PA: WB Saunders Co.; 2006;p. 1361–1370
  23. Damsa C, Bumb A, Bianchi-Demicheli F, et al. Dopamine dependent” side effects of SSRIs: a clinical review. J Clin Psychiatry. 2004;65:1064–1068
  24. Ellsworth AJ, Witt DM, Dugdale DC, et al. Mosby's Medical Drug Reference. St. Louis, MO: Mosby; 2006;
  25. Patterson WM. Fluoxetine-induced sexual dysfunction. J Clin Psychiatry. 1993;54:71
  26. Gold Standard, Inc. Citalopram, Escitalopram, Fluoxetine, Fluoxetine+Olanzapine, Fluvoxamine, Paroxetine, and Sertraline: Adverse Reactions. MD Consult [database] 2008. Columbia, SC: University of South Carolina School of Medicine Library. Accessed January 30, 2008.
  27. Hirschfeld RMA. The role of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry. 2005;66(Suppl 3):3–4
  28. Masand PS, Gupta S. Long-term side effects of newer-generation antidepressants: SSRIs, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry. 2002;14(3):175–182
  29. Melkersson K. Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J Clin Psychiatry. 2005;66(6):761–767
  30. Isojarvi JIT, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med. 1993;329:1383–1388

PII: S1054-139X(08)00679-4

doi: 10.1016/j.jadohealth.2008.11.010

Journal of Adolescent Health
Volume 45, Issue 1 , Pages 70-76 , July 2009

Article Tools